A Phase 1 interventional study of PD-0332991 alone and Tamoxifen 60 mg in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-08.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A single 125 mg oral dose of the investigational compound PD-0332991 will be administered alone and after steady-state dosing of tamoxifen to determine if coadministration of tamoxifen alters the plasma pharmacokinetics of PD-0332991 in healthy male volunteers.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
Drug: PD-0332991 alone · Drug: Tamoxifen 60 mg · Drug: Tamoxifen 20 mg · Drug: PD-0332991 combination
PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
Also known as: PD-0332991, palbociclib
On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
Drug page: Palbociclib
PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
Also known as: PD-0332991, palbociclib
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of PD-0332991
AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).
Time frame: 0-144 hrs post PD-0332991 dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PD-0332991
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: 0-144 hrs post PD-0332991 dose
Maximum Observed Plasma Concentration (Cmax) of PD-0332991
Time frame: 0-144 hrs post PD-0332991 dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991
Time frame: 0-144 hrs post PD-0332991 dose
Plasma Decay Half-Life (t1/2) of PD-0332991
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: 0-144 hrs post PD-0332991 dose
Apparent Oral Clearance (CL/F) of PD-0332991
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: 0-144 hrs post PD-0332991 dose
Apparent Volume of Distribution (Vz/F) of PD-0332991
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: 0-144 hrs post PD-0332991 dose
Minimum Observed Plasma Trough Concentration (Cmin) of tamoxifen
Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2
Minimum Observed Plasma Trough Concentration (Cmin) of 4-hydroxytamoxifen
Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2
Minimum Observed Plasma Trough Concentration (Cmin) of N-desmethyltamoxifen
Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2
Minimum Observed Plasma Trough Concentration (Cmin) of endoxifen
Time frame: Days 1, 5, 12, 21, 22, and 28 of Period 2
The record gives a start of Apr 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib